This biopharmaceutical company is focused on treating two severe and ultra-rare disorders. Its lead product, Soliris, is the only drug approved for patients with an extremely rare and life-threatening blood disease referred to as PNH (paroxysmal nocturnal hemoglobinuria). Alexion reported $274 million worth of second-quarter sales of Soliris, up 48% from the same period last year. The company credited the growth to increasing numbers of patients being treated with the drug globally. It follows Soliris's approval in the U.S. and European Union late last year as the first and only treatment for patients with an ultra-rare genetic disease known as Atypical Hemolytic Uremic Syndrome (aHUS). -- N.S.
(3-year annual rate)
|Northern Oil and Gas||237%|
|Green Mountain Coffee Roasters||78%|